One of 168澳洲幸运5官方开奖结果历史:Pedro Acosta’s top options, if 🐟he leaves KTM, have been dismissed as a🍌 realistic destination.

The saga surrounding Acosta is at the epicentre of the MotoGP rider market this year.

He is contracted to KTM until the end of next year, providing a ꦇmajor complication if he seeks an exit.

But Acosta, and his manager Albert Valera, have con🦹tinually b😼een linked with leaving his current manufacturer who have seen their competitiveness wane this year.

'The problem' with signing Pedro Acosta pinpointed

VR46 are an obvious option. Valentino Ro🎉ssi sees Acosta as the man who could deny Marc Marquez anotheꦏr MotoGP title in 2026, which would either t🐼ie or beat Rossi’s own tally.

Rossi’s team also have access to one f🧜actory-spec Ducati, currently in tಌhe hands of Fabio di Giannantonio, which they could tempt Acosta with.

But they have been shot down as a realis🌄tic alternative for Acosta in 2026.

“Lots of talk swirling around. Nobody knows,” TNT Sports’ Gavin Emmet🔯t said.

“But the general🔯 talk around the paddock is that they are looking for a♋ way out.

“The problem is tജhat the release clause in his KTM contract is very, very high.

“People say VR46? There is no way on this Earth 𒁏that VR46 will pay €6m, or whatever the talk i▨s, to get someone out of a contract.

“That’s before you pay them.

“I could see a factory Honda going for it.”

Michael Laverty added: “He’s got a good man on the case, Albert ♔Vꩵalera.

“He will be working haღrd, trying to negotiate somet🎃hing.

“Ho𝓡nda have the resources and the cheque book could get opened.”

Honda will also reportedly 168澳洲幸ꦿ运5官方开奖结果历史:ma💮ke a big-money offer for Toprak Razgatlioglu.

The once-mighty Japanese manufacturer dreams of a formidable rider line-up, twinning🎃 Razgatlioglu with Acosta.

For now, they have Joan Mir and Luca Marini on✨ their f๊actory bikes.

Jo💖hann Zarco, the LCR rider, has often impressed on a Honda.

Suddenly, after yꦗears of being below par, the performances of the Hondas th🔥is season has made them an attractive destination for 2026 and beyond.